Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Aug 7;124(6):836.
doi: 10.1182/blood-2014-06-578948.

Gaining experience with the NOACs

Pieter W Kamphuisen  1
Affiliations
Comment

Gaining experience with the NOACs

Pieter W Kamphuisen. Blood. .

Abstract

In this issue of Blood, Beyer-Westendorf et al analyzed the safety of long-term treatment with the novel oral anticoagulant (NOAC) factor Xa inhibitor, rivaroxaban, in a large registry of patients from their clinical practice with either venous thromboembolism (VTE) or atrial fibrillation. During treatment, the annual major bleeding rate associated with rivaroxaban treatment was 3% to 4%, and did not differ between patients with VTE or atrial fibrillation. In addition, 60% of the major bleeding events were treated conservatively, by compression therapy or blood transfusion. Finally, the mortality rate due to bleeding after 90 days of treatment was 6.3%. All together, this study provides valuable data on the safety of rivoraxaban. Valuable, because most data on the safety of NOACs come from the phase 3 trials and not from clinical practice.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: P.W.K. is a consultant for Boehringer Ingelheim and is a steering committee member of the ongoing dabigatran reversal study with idarucizumab.

Comment on

References

    1. Beyer-Westendorf J, Förster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124(6):955-962. - PMC - PubMed
    1. Shah N, Gosch K, Chan P, Marzec L, Ting H. Use of novel oral anticoagulants for patients with non-valvular atrial fibrillation: results from the NCDR Pinnacle Registry. J Am Coll Cardiol. 2014;63(12_S)
    1. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962. - PubMed
    1. van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014;12(3):320–328. - PubMed
    1. Levi M, Hovingh K. Bleeding complications in patients on anticoagulants who would have been disqualified for clinical trials. Thromb Haemost. 2008;100(6):1047–1051. - PubMed